Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
Sebastian Stintzing(Humboldt-Universität zu Berlin), Volker Heinemann(LMU Klinikum), Alexander Kiani(Bayreuth Medical Center), Thomas Decker, Markus Moehler(Johannes Gutenberg University Mainz), A. Jagenburg, Martina Stauch, Ursula Vehling‐Kaiser(University of Applied Sciences Landshut), S-E. Al-Batran(Krankenhaus Nordwest), Dominik Paul Modest(Berliner Hochschule für Technik), Swantje Held(AIO Studien gGmbH), Andreas Jung(Ludwig-Maximilians-Universität München), Christoph Kahl(Klinikum Magdeburg), Tobias Heintges(Lukaskrankenhaus), Ludwig Fischer von Weikersthal(Praxis für Hämatologie und Onkologie), Werner Scheithauer(Comprehensive Cancer Center Vienna), G. Seipelt, Lisa Miller‐Phillips(Ludwig-Maximilians-Universität München), Frank Kullmann(Klinikum Weiden), Thomas Kirchner(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cited by 139
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
|New England Journal of Medicine|2021|1.7k